Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
"NOVARTIS NEW ZEALAND LIMITED, Clinician",Dabrafenib and trametinib,"Melanoma, stage III/IV with BRAF V600 mutation","Dabrafenib and trametinib (Mekinist,Tafinlar)",,Community and Hospital,Oncology Agents and Immunosuppressants
